Global pharma majors are opting for joint venture route to tap the consumption story in India,one of the world’s key markets,as high valuations are acting as deterrent for M&A deals,believe experts.
So far this year,two global pharma majors have entered the Indian market through JV route.
In January,Germany’s Bayer Healthcare announced a joint venture with Zydus Cadila to sell drugs in India and in April,Sun Pharmaceutical Industries and US-based Merck & Co Inc entered into a joint venture agreement to develop,produce and market generic drugs in emerging markets.
Commenting on the trend,Mergermarket Asia Pacific Deputy Editor Anjali Naik said,”especially for MNCs who don’t have existing regional operations,it makes sense to take a JV route as opposed to an acquisition.


